Micro-Tech Acquires Key CONMED GI Lines in Strategic Market Shift

ANN ARBOR, Mich. – March 18, 2026 – In a significant strategic realignment within the medical device sector, Micro-Tech Endoscopy has entered into a definitive agreement to acquire the global distribution rights for the Duraclip™, Precisor®, and Optibite® product lines from CONMED Corporation. The move, announced today, follows CONMED's decision to exit the gastroenterology (GI) market and brings these established product lines under the direct control of their original manufacturer, Micro-Tech.

This transaction is poised to reinforce Micro-Tech's portfolio in the competitive GI endoscopy space while ensuring uninterrupted access to critical tools for clinicians worldwide. For CONMED, the divestment marks a pivotal step in a broader strategy to refine its focus on core, higher-growth surgical markets.

CONMED's Strategic Divestment

CONMED Corporation's departure from the gastroenterology sector is a calculated decision rooted in a company-wide "portfolio optimization strategy." The company aims to concentrate its resources and operational efforts on what it identifies as higher-growth and higher-margin business segments. The GI product lines, while significant, were determined to be outside this sharpened focus.

Financially, the divested lines were substantial, projected to generate between $90 million and $95 million in revenue during fiscal year 2025. While CONMED anticipates an earnings per share (EPS) dilution of approximately $0.45 to $0.55 in 2026 as a result of the exit, the company projects a long-term benefit. The strategic shift is expected to enhance CONMED's consolidated gross margin profile by an estimated 80 basis points once fully realized. The company has reaffirmed its 2025 financial guidance, indicating the move will not materially affect the current fiscal year's results.

With this divestment, CONMED will now intensify its investments and strategic initiatives in its core markets. These include orthopedic surgery, which accounted for 42% of its net sales in 2025, and general surgery, which contributed 58%. The company plans to drive growth through innovative products such as its AirSeal insufflation system, Buffalo Filter smoke evacuation devices, and the BioBrace implant technology, concentrating on leadership in minimally invasive, robotic, and laparoscopic procedures.

Micro-Tech Consolidates Power in GI Endoscopy

The acquisition is a landmark move for Micro-Tech Endoscopy, a global leader in minimally invasive medical devices founded in 2000. While CONMED has distributed the Duraclip™, Precisor®, and Optibite® products for over a decade, Micro-Tech has always been the original equipment manufacturer (OEM). This transaction effectively brings these product lines "home," transitioning Micro-Tech from a behind-the-scenes manufacturer to the direct, forward-facing manager of their market presence.

By integrating these products, Micro-Tech significantly strengthens its offerings. The addition of the Duraclip™ Repositionable Hemostasis Clip enhances its hemostasis portfolio, a critical area for managing GI bleeding. Meanwhile, the Precisor® Biopsy Forceps and Optibite® Polypectomy Snares expand the reach and depth of its biopsy and therapeutic lines. These products will now sit alongside Micro-Tech's other innovations, such as the Dual Action Tissue (DAT) Closure device and the eyeMAX cholangioscopy system, creating a more comprehensive and powerful suite of tools for gastroenterologists.

"This agreement reflects our continued commitment to expanding access to a broad range of GI endoscopy tools," said Scott VanderMeer, President of Micro-Tech Endoscopy Americas. "By adding Duraclip, Precisor, and Optibite to our portfolio, we are strengthening our position in the GI market and reinforcing our role as a trusted partner to clinicians."

Market Impact and Continuity of Care

The global GI endoscopy devices market is a dynamic and growing field, valued at approximately $4.8 billion in 2024 and projected to exceed $7.6 billion by 2033. This growth is fueled by an aging population, a rising prevalence of gastrointestinal disorders, and an increasing preference for minimally invasive diagnostic and therapeutic procedures. In this highly competitive landscape, dominated by giants like Olympus, Boston Scientific, and Medtronic, Micro-Tech's strategic acquisition of established brands provides a distinct advantage.

For clinicians and hospital administrators, the primary concern during such transitions is the continuity of care and product availability. Micro-Tech's role as the original manufacturer is a key factor in alleviating these concerns. The company's deep, intrinsic knowledge of the design, production, and quality control of these devices positions it to ensure a seamless transition with minimal disruption to the supply chain.

CONMED executives have expressed confidence in the handover. "We are pleased to transition these product lines from CONMED to Micro-Tech and believe they are well positioned to continue the strong legacy these products have established in the GI market," stated Pete Shagory, Vice President & General Manager of Advanced Endoscopic Technologies at CONMED. He further noted, "Micro-Tech has long served as the original manufacturer behind the Duraclip, Precisor, and Optibite devices and brings extensive experience in its design and production. We are committed to supporting a smooth transition for customers."

Upon closing of the transaction, which is subject to customary conditions, Micro-Tech plans to fully integrate the product lines into its extensive U.S. and global commercial operations. With a presence in over 90 countries, the company's existing infrastructure is well-equipped to manage the expanded distribution and customer support, ensuring that clinicians who rely on these tools can continue to do so with confidence.